Your session is about to expire
← Back to Search
T-allo10 for Blood Disorders (T-allo10 Trial)
T-allo10 Trial Summary
This trial is for a cell therapy, T-allo10, that would prevent GvHD in patients receiving mismatched related or unrelated donor HSCT for hematologic malignancies. This is the first trial of its kind in pediatric patients and is only available at Lucile Packard Children's Hospital, Stanford.
T-allo10 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowT-allo10 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.T-allo10 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have an ongoing, untreated infection.I have a serious health condition that could make treatment risky.I had a bone marrow or stem cell transplant in the last 6 months.I have a donor who is an 8/10 or 9/10 match for my transplant.My kidneys, liver, lungs, and heart are functioning well.I have a donor who matches my HLA type.My condition is a type of blood cancer beyond the first remission.I have a history of major kidney, liver, lung, or heart problems.I am mostly active and can carry out daily activities without significant help.I agree to use effective birth control methods.I am between 3 and 45 years old, or at least 12 for specific study groups.
- Group 1: Cohort 1
- Group 2: Cohort 2
- Group 3: Cohort 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research study enrolling elderly individuals?
"As per the requirements of this research project, children aged 3 and above but not exceeding 45 years old may take part."
To what extent is the current clinical trial being populated?
"That is correct. According to clinicaltrials.gov, this research study has been actively recruiting since August 30th 2017 and was last updated on February 2nd 2022; it requires a total of thirty participants from one site."
Are there still openings in this experiment for volunteers?
"This clinical trial is currently recruiting participants, as indicated on the clinicaltrials.gov website. This research was initially posted in August 2017 and has been updated most recently in February 2022."
Has the United States Food and Drug Administration sanctioned T-allo10?
"Our experts at Power rate T-allo10's safety as a 1, which is customary for Phase 1 clinical trials where there are only limited data indicating its efficacy and safety."
Is there an opportunity to participate in this clinical experiment?
"This clinical trial necessitates 30 individuals aged 3 to 45 suffering from lymphoma or Hodgkin's disease, who have been classified as CR1-ultra high risk, hypodiploidy positive, and/or possess one of the other CR3 qualifiers."
Share this study with friends
Copy Link
Messenger